- Home
- INCY vs KEP Comparison
INCY vs KEP Comparison
Compare INCY & KEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- KEP
- Stock Information
- Founded
- INCY 1991
- KEP 1961
- Country
- INCY United States
- KEP South Korea
- Employees
- INCY N/A
- KEP N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- KEP Electric Utilities: Central
- Sector
- INCY Health Care
- KEP Utilities
- Exchange
- INCY Nasdaq
- KEP Nasdaq
- Market Cap
- INCY 13.4B
- KEP 12.1B
- IPO Year
- INCY 1993
- KEP N/A
- Fundamental
- Price
- INCY $67.11
- KEP $11.05
- Analyst Decision
- INCY Hold
- KEP
- Analyst Count
- INCY 20
- KEP 0
- Target Price
- INCY $71.94
- KEP N/A
- AVG Volume (30 Days)
- INCY 1.9M
- KEP 422.3K
- Earning Date
- INCY 07-29-2025
- KEP 06-16-2025
- Dividend Yield
- INCY N/A
- KEP N/A
- EPS Growth
- INCY N/A
- KEP 667.18
- EPS
- INCY 0.10
- KEP 5.56
- Revenue
- INCY $4,413,226,000.00
- KEP $64,053,841,898.00
- Revenue This Year
- INCY $13.29
- KEP $5.65
- Revenue Next Year
- INCY $10.47
- KEP $2.21
- P/E Ratio
- INCY $691.99
- KEP $3.93
- Revenue Growth
- INCY 17.13
- KEP 4.91
- 52 Week Low
- INCY $53.56
- KEP $6.68
- 52 Week High
- INCY $83.95
- KEP $11.43
- Technical
- Relative Strength Index (RSI)
- INCY 66.68
- KEP 69.81
- Support Level
- INCY $63.51
- KEP $10.66
- Resistance Level
- INCY $66.26
- KEP $11.43
- Average True Range (ATR)
- INCY 1.92
- KEP 0.24
- MACD
- INCY 0.30
- KEP 0.01
- Stochastic Oscillator
- INCY 67.34
- KEP 83.04
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.